-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350

Benzinga·07/31/2026 16:05:46
Listen to the news
Oppenheimer analyst Kostas Biliouris maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $500 to $350.